Physician profile
Sheldon B Pike
NPI 1225050412
$5,938.30
in general payments reported to CMS, 2019-2025
33 companies · $697 in 2025
The $697 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $851 · 2021: $1,006 · 2022: $972 · 2023: $701 · 2024: $904 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.34 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,185.28 | 2021-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $889.37 | 2019-2025 | Erleada, Akeega |
| Neotract INC. | $639.59 | 2019-2020 | |
| Axonics, INC. | $498.92 | 2020-2024 | Axonics, Bulkamid |
| Pfizer INC. | $339.41 | 2019-2024 | |
| Astellas Pharma US INC | $338.80 | 2019-2024 | Xtandi |
| Boston Scientific Corporation | $321.61 | 2019-2025 | Spaceoar Vue System - 10ml |
| Myriad Genetic Laboratories, INC. | $234.97 | 2021-2025 | Prolaris, Myrisk |
| Olympus America INC. | $201.90 | 2021-2025 | Itind System |
| Sumitomo Pharma America, INC. | $174.65 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $172.37 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $145.03 | 2019-2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $91.45 | 2019-2023 | Aveed, Xiaflex |
| Urovant Sciences INC | $82.01 | 2022 | |
| Myovant Sciences INC. | $70.67 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $53.87 | 2020-2021 | |
| Genzyme Corporation | $52.78 | 2022 | |
| Baxter Healthcare | $52.62 | 2021 | |
| Progenics Pharmaceuticals, INC. | $39.76 | 2023-2025 | Pylarify |
| Accord Healthcare, INC. | $38.59 | 2022-2025 | |
| Dentsply Ih Ab | $38.51 | 2023 | Lofric |
| Tolmar, INC. | $38.38 | 2024-2025 | Jatenzo |
| Therapeuticsmd, INC. | $36.92 | 2019 | |
| Verity Pharmaceuticals INC. | $31.92 | 2025 | Trelstar |
| E.R. Squibb & Sons, L.L.C. | $31.30 | 2022 | |
| Urogen Pharma, INC. | $19.36 | 2025 | |
| Acerus Pharmaceuticals Corporation | $18.74 | 2022 | |
| Dentsply Ih INC. | $17.78 | 2021 | |
| Amarin Pharma, INC. | $17.65 | 2019 | |
| Abbvie INC. | $17.43 | 2024 | |
| Antares Pharma, INC. | $17.03 | 2024 | Xyosted |
| Coloplast Corp | $15.93 | 2019 | |
| Endo USA, INC. | $13.70 | 2024 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Pike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.